A report from IMS Institute for Healthcare Informatics shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan.

Key facts in the report include:

  • Of the seven countries analyzed, only Italy had a lower average net cost than the United States for a 12-week course of Hepatitis C drug treatment, but Italy had a far lower treatment rate.
  • At $50,400, the net U.S. price per course of treatment for Harvoni was below the net price in France, Japan, Spain, Germany, and the U.K. in 2015.
  • Net prices in the U.S. for Sovaldi was below the European average price of $45,055.
  • Average discounts on Hepatitis C medications were 15-20% off list prices in the countries examined, except in the U.S. where discounts of 45-55% were been disclosed for Sovaldi and Harvoni.
  • The Medicare Part D program accounted for about half of estimated U.S. prevalence and treatment volume for Hepatitis C in 2015.

Read the full report.